The global vaccines market is estimated at $41bn in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period. The Paediatric Vaccines segment held 56% of the Global Vaccines market in 2018.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 201-page report you will receive 121 charts– all unavailable elsewhere.
The 201-page report provides clear detailed insight into the global vaccines sales market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Vaccines Sales Market forecasts from 2019-2029
• Global Vaccines Sales Market forecasts from 2019-2029 by Submarket: • Paediatric Vaccines • Adult Vaccines • Elderly Vaccines • Travel Vaccines • Therapeutic Vaccines
• Global Vaccines Sales Market forecasts from 2019-2029 by Leading Vaccines: • Prevnar • Gardasil • Fluzone • Pentacel • ProQuad • Infanrix/Pediarix • Zostavax • RotaTeq • Hepatitis Vaccines • Menactra
• Global Vaccines Sales Market forecasts from 2019-2029 by Regional and National Market: • US • EU5: Germany, France, Italy, UK, Spain • Japan • Brazil • Russia • India • China
• Profiles of the selected leading companies: • AstraZeneca • Eli Lilly • Emergent BioSolutions Inc. • GlaxoSmithKline • Johnson & Johnson • Merck & Co. • Pfizer • Sanofi • Serum Indian Institute Pvt. Ltd. • Takeda
• The Vaccines Market Pipeline Analysis
• A SWOT and STEP analysis of the global vaccines market
• Key Questions Answered by this Report: • What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029? • What are the main drivers and restraints that will shape the overall vaccines market over the next ten years? • What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why? • What factors will affect that industry and market over the next ten years? • What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2028? • How will political and regulatory forces influence regional markets? • How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029? • Who are the leading companies and what are their activities, results, developments and prospects? • What are the leading vaccines? What are their revenues and latest developments? • What are some of the most prominent human vaccines currently in development? • What are the main trends that will affect the world vaccines market between 2018 and 2029? • What are the main strengths, weaknesses, opportunities and threats for the market? • What are the social, technological, economic and political influences that will shape that industry over the next ten years? • How will the global vaccines market evolve over the forecasted period, 2018 to 2029? • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029? • Which therapies can succeed and what revenues could they generate to 2029? • What will be the main commercial drivers for the market from 2018 to 2029? • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth? • How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Vaccines Sales Market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Overview of the World Vaccines Market 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analytical Study 1.5 Who is This Report For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2. Introduction to the World Human Vaccines Market 2.1 Human Vaccines - Aiming for Global Disease Prevention 2.2 What is the Social and Economic Burden? 2.3 Vaccine Technology 2.3.1 Inactivated Vaccines 2.3.2 Live Attenuated Vaccines 2.3.3 Conjugate Vaccines 2.3.4 Recombinant Vector Vaccines 2.4 Key Influencers of the Human Vaccine Market 2.4.1 Governments and International Organizations 2.4.1.1 The World Health Organisation (WHO) 2.4.1.2 The Governmental Influence 2.4.2 Leading Manufacturers 2.4.2.1 Merck& Co. 2.4.2.2 Sanofi 2.4.2.3 GlaxoSmithKline 2.4.2.4 Pfizer 2.5 Human World Vaccines – Market Segmentation 2.5.1 Paediatric Vaccines 2.5.2 Adult Vaccines 2.5.3 Elderly Vaccines 2.5.4 Travel Vaccines 2.5.5 Therapeutic Vaccines
3. World Vaccine Market Outlook, 2019-2029 3.1 World Vaccine Market, 2018 3.1.1 Paediatric Vaccines Maintains Constant Demand 3.1.2 Ageing Population Requires More Care 3.1.3 Emerging Markets Demand Better Immunity 3.2 The World Human Vaccines Forecast, 2019-2029 3.3 The World Vaccine Market: Industry Trends 3.3.1 Undulating Demand 3.3.2 Supply Restraints 3.3.3 Funding Trends 3.3.4 Protecting the Workforce of an Economy
4. World Vaccine Submarkets: Prospects, 2019-2029 4.1 Paediatric Vaccines 4.1.1 Paediatric Vaccine Forecast, 2019-2029 4.1.2 Paediatric Vaccine Trends 4.1.2.1 Innovative Delivery 4.1.2.2 Fear Factor 4.1.2.3 Novel Vectors 4.2 Adult Vaccines 4.2.1 Adult Vaccine Forecast, 2019-2029 4.2.2 Adult Vaccine Trends 4.2.2.1 Fighting the Flu 4.2.2.2 HPV 4.2.2.3 Repeat Doses for Continued Protection 4.3 Elderly Vaccines 4.3.1 Elderly Vaccine Forecast, 2019-2029 4.3.2 Elderly Vaccine Trends 4.3.2.1 With Age Comes Greater Risk 4.3.2.2 Ageing Population across the Globe 4.4 Travel Vaccines 4.4.1 Travel Vaccines Forecast, 2018-2029 4.4.2 Travel Vaccine Trends 4.4.2.1 Zika Virus Outbreak 4.4.2.2 Globalization Carries Diseases 4.5 Therapeutic Vaccines 4.5.1 Therapeutic Vaccine Trends
6. Regional and Leading Developed National Vaccines Markets, 2019-2029 6.1 North America Vaccine Market, 2019-2029 6.1.1 The US Vaccine Market, 2018 6.1.2 The US Vaccine Market Forecast, 2019-2029 6.2 Japanese Vaccine Market, 2019-2029 6.2.1 The Japanese Vaccine Market, 2018 6.2.2 The Japanese Vaccine Market Forecast, 2019-2029 6.2.3 Addressing the Alleged Vaccine Gap 6.3 EU5 Vaccine Market, 2019-2029 6.3.1 The EU5 Vaccine Market, 2018 6.3.2 The EU5 Vaccine Market Forecast, 2019-2029 6.4 United Kingdom Vaccine Market, 2019-2029 6.4.1 The UK Vaccine Market, 2018 6.4.2 The UK Vaccine Market Forecast, 2019-2029 6.5 France: Vaccine Market, 2019-2029 6.5.1 The French Vaccine Market, 2018 6.5.2 The French Vaccine Market Forecast, 2019-2029 6.5.3 French Healthcare System – Immunization Policy 6.6 Germany: Vaccine Market, 2019-2029 6.6.1 The German Vaccine Market, 2018 6.6.2 The German Vaccine Market Forecast, 2019-2029 6.7 Italy: Vaccine Market, 2019-2029 6.7.1 The Italian Vaccine Market, 2018 6.7.2 The Italian Vaccine Market Forecast, 2019-2029 6.7.3 Challenges in Public Healthcare 6.8 Spain: Vaccine Market, 2019-2029 6.8.1 The Spanish Vaccine Market, 2018 6.8.2 The Spanish Vaccine Market Forecast, 2019-2029 6.8.3 District Rules – Economic Challenges
7. Leading Emerging National Markets, 2019-2029 7.1 China: Vaccine Market, 2019-2029 7.1.1 The Chinese Vaccine Market, 2018 7.1.2 The Chinese Vaccine Market Forecast, 2019-2029 7.1.3 Setting-Up Domestic Vaccine Industries 7.2 India: Vaccine Market, 2019-2029 7.2.1 The Indian Vaccine Market, 2018 7.2.2 The Indian Vaccine Market Forecast, 2019-2029 7.2.3 The Extent to which the Vaccine Market Can Flourish? 7.3 Brazil: Vaccine Market, 2019-2029 7.3.1 The Brazilian Vaccine Market, 2018 7.3.2 The Brazilian Vaccine Market Forecast, 2019-2029 7.3.3 Zika Outbreak 7.4 Russia: Vaccine Market, 2019-2029 7.4.1 The Russian Vaccine Market, 2018 7.4.2 The Russian Vaccine Market Forecast, 2019-2029 7.4.3 Power of the State
8. Leading Manufacturers of Vaccines for Human Use 8.1 GlaxoSmithKline (GSK) 8.1.1 GSK Vaccine Performance 8.1.2 GSK Developments 8.1.2.1 Mergers and Acquisitions 8.1.2.2 GSK Vaccine Pipeline 8.2 Merck& Co. 8.2.1 Merck Vaccine Performance 8.2.2 Merck Developments 8.2.2.1 Merck Market Movements 8.2.2.2 Collaborations 8.2.2.3 Merck Pipeline 8.3 Sanofi 8.3.1 Sanofi Vaccine Performance 8.3.2 Sanofi Developments 8.3.2.1 Acquisitions & Expansions 8.3.2.2 Sanofi Vaccine Pipeline 8.4 Pfizer 8.4.1 Pfizer Vaccine Performance 8.4.1.1 Financial Overview 8.4.2 Pfizer Developments 8.4.2.1 Pfizer Mergers & Acquisitions 8.4.2.2 Pfizer Pipeline 8.5 Johnson & Johnson 8.5.1 Financial Overview 8.6 AstraZeneca 8.6.1 Financial Overview 8.7 Eli Lilly and Company 8.7.1 Eli Lilly and Company Vaccine Performance 8.7.1.1 Financial Overview 8.7.2 Eli Lilly and Company Developments 8.8 Takeda Pharmaceutical Company Limited 8.8.1 Takeda Pharmaceutical Company Limited Vaccine Performance 8.8.1.1 Financial Overview 8.9 Serum Institute of India Private Limited 8.9.1 Serum Institute of India Private Limited Vaccine Performance 8.10 Emergent BioSolutions Inc. 8.10.1 Emergent BioSolutions Inc. Vaccine Performance 8.11 Key Strategic Acquisitions and Collaborations 8.12 Other Companies Serving the Vaccines Market
10. Qualitative Analysis of the World Vaccines Market 10.1 SWOT Analysis of the World Human Vaccines Market 10.1.1 Strengths 10.1.1.1 Ageing Population 10.1.1.2 Prevention is Better than Cure 10.1.1.3 Demand from Emerging Markets Continue 10.1.1.4 Promising R&D Pipeline 10.1.1.5 Increasing Awareness 10.1.2 Weaknesses 10.1.2.1 High Manufacturing Costs 10.1.2.2 Time Constraints 10.1.2.3 Barriers to Market Entry 10.1.3 Opportunities 10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods 10.1.3.2 Shifting Focus on Adults Vaccines 10.1.4 Threats 10.1.4.1 Oligarchic Presence of Pharmaceutical Giants 10.1.4.2 Productivity Gap 10.2 STEP Analysis of the World Human Vaccines Industry and Market 10.2.1 Social Factors 10.2.1.1 Maintaining a Healthier Workforce 10.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects 10.2.2 Technological Forces 10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics 10.2.3 Economic Factors 10.2.3.1 High Costs of Production 10.2.3.2 Soaring Vaccines Demand from Developing Countries 10.2.4 Political Factors 10.2.4.1 Governments Play Crucial Roles in Vaccination
11. Conclusions 11.1 Segment Market Share Shift 11.2 Elderly People Become the New Target Market 11.3 Endemic Infections Drive Travel Vaccines Growth 11.4 Emerging Markets: High Demand for Vaccines 11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth 11.6 Strong and Diverse Research and Development 11.7 Concluding Remarks
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Tables Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2019-2029 Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn), AGR (%), CAGR (%), 2019-2029 Table 4.2 World Vaccines Submarkets: Market Shares (%), 2017-2029 Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.1 Prevnar Revenue ($bn), 2014-2017 Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.3 Gardasil Revenue ($bn), 2014-2017 Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2014-2017 Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.7 Pentacel Revenue ($bn), 2014-2017 Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2014-2017 Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.11 Infanrix/Pediarix Revenue ($bn), 2014-2016 Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.13 Zostavax Revenue ($bn), 2014-2017 Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.15 RotaTeq Revenue ($bn), 2014-2017 Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 5.17 GSK Hepatitis Vaccines Revenue ($bn), 2014-2016 Table 5.18 GSK Hepatitis Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029 Table 5.19 Menactra Revenue ($bn), 2014-2017 Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029 Table 6.1 Leading National Market Revenue Forecasts ($bn), 2018, 2023, 2029 Table 6.2 Leading Developed National Markets Revenue Forecasts ($bn), 2018, 2023, 2029 Table 6.3 Leading Developed National Market Shares (%), 2018, 2023, 2029 Table 6.4 North America Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%) and CAGR (%), 2019-2029 Table 6.5 North America Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029 Table 6.6 The US Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029 Table 6.7 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 6.8 Europe Vaccines Revenue Forecast by Submarkets ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 6.9 Europe Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2019-2029 Table 6.10 The EU5 Vaccines World Market Shares (%), 2018, 2023, 2029 Table 6.11 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 6.12 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 6.13 The French Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 6.14 The German Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 6.15 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 6.16 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 7.1 Asia-Pacific Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 7.2 Asia-Pacific Vaccines Revenue Forecast, By Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029 Table 7.3 Leading Emerging National Market Revenue Forecasts ($bn), 2018, 2023, 2029 Table 7.4 Leading Emerging National Market Shares (%), 2018, 2023, 2029 Table 7.5 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029 Table 7.6 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029 Table 7.7 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029 Table 7.8 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share and CAGR (%), 2019-2029 Table 9.1 Prophylactic Vaccines in Development, 2018 Table 9.2 Paediatric Vaccines in Development, 2018 Table 9.3 Adult Vaccines in Development, 2018 Table 9.4 Elderly Vaccines in Development, 2018 Table 9.5 Travel Vaccines in Development, 2018 Table 9.6 Therapeutic Vaccines in Development, 2018
List of Figures Figure 1.1 World Vaccines Market Segmentation, 2017 Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2018 Figure 3.2 World Vaccines Leading National Market Shares (%), 2018 Figure 3.3 World Vaccines Leading National Market Shares (%), 2023 Figure 3.4 World Vaccines Leading National Market Shares (%), 2029 Figure 3.5 World Vaccines Market: Drivers and Restraints Figure 4.1 World Vaccines Submarket (%) Segmentation, 2018 Figure 4.2 World Paediatric Vaccines Market Share (%), 2019 Figure 4.3 World Paediatric Vaccines Market Share (%), 2023 Figure 4.4 World Paediatric Vaccines Market Share (%), 2029 Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2019-2029 Figure 4.6 World Adult Vaccines Market Share (%), 2019 Figure 4.7 World Adult Vaccines Market Share (%), 2023 Figure 4.8 World Adult Vaccines Market Share (%), 2029 Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2019-2029 Figure 4.10 World Elderly Vaccines Market Share (%), 2019 Figure 4.11 World Elderly Vaccines Market Share (%), 2023 Figure 4.12 World Elderly Vaccines Market Share (%), 2029 Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2019-2029 Figure 4.14 World Travel Vaccines Market Share (%), 2019 Figure 4.15 World Travel Vaccines Market Share (%), 2023 Figure 4.16 World Travel Vaccines Market Share (%), 2029 Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2019-2029 Figure 5.1 Prevnar Revenue Forecast ($bn), 2019-2029 Figure 5.2 Gardasil Revenue Forecast ($bn), 2019-2029 Figure 5.3 Fluzone Revenue Forecast ($bn), 2019-2029 Figure 5.4 Pentacel Revenue Forecast ($bn), 2019-2029 Figure 5.5 ProQuad / M-M-R II / VarivaxRevenue Forecast ($bn), 2019-2029 Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2019-2029 Figure 5.7 Zostavax Revenue Forecast ($bn), 2019-2029 Figure 5.8 RotaTeq Revenue Forecast ($bn), 2019-2029 Figure 5.9 GSK Hepatitis Vaccines Revenue Forecast ($bn), 2019-2029 Figure 5.10 Menactra Revenue Forecast ($bn), 2019-2029 Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2019-2029 Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2019-2029 Figure 6.3 EU5 Vaccines Market Share (%), 2018 Figure 6.4 EU5 Vaccines Market Share (%), 2023 Figure 6.5 EU5 Vaccines Market Share (%), 2029 Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2019-2029 Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2019-2029 Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2019-2029 Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2019-2029 Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2019-2029 Figure 7.1 BRIC Countries Vaccines Market Share (%), 2018 Figure 7.2 BRIC Countries: Vaccines Market Share (%), 2023 Figure 7.3 BRIC Countries: Vaccines Market Share (%), 2029 Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2019-2029 Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2019-2029 Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2019-2029 Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2019-2029 Figure 8.1 GSK Vaccines Revenue ($bn), 2015-2017 Figure 8.2 GSK Vaccines Region Breakdown (%), 2017 Figure 8.3 Merck Vaccines Revenue (%), 2017 Figure 8.4 Sanofi Vaccines Revenue ($bn), 2014-2017 Figure 8.5 Pfizer Revenue ($bn), 2014-2017 Figure 8.6 J&J Revenue ($bn), 2014-2017 Figure 8.7 AstraZeneca Revenue ($bn), 2014-2017 Figure 8.8 Eli Lilly and Company Revenue ($bn), 2014-2017 Figure 8.9 Takeda Pharmaceutical Revenue ($bn), 2014-2017 Figure 10.1 SWOT Analysis of the World Vaccines Market Figure 10.2 STEP Analysis of the World Vaccines Market Figure 11.1 World Paediatric Vaccines Revenue Forecast ($bn), 2018-2029 Figure 11.2 World Elderly Vaccines Revenue Forecast ($bn), 2018-2029 Figure 11.3 Asia-Pacific Vaccines Revenue Forecast (% Share), 2018-2029
AstraZeneca Bavarian Nordic Bayer Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) Binnopharm BiondVax Bristol-Myers Squibb Chemo-Sero-Therapeutic Research Institute China National Biotec Group Denka Seiken Eli Lilly Emergent BioSolutions Inc Fresenius GlaxoSmithKline (GSK) GlaxoWellcome Henogen Immatics InterveXion Therapeutics Johnson & Johnson LigoCyte MedImmune Merck & Co. Merck Sharp & Dohme Corp Nanolek NewLink Genetics Okairos PaxVax Pfizer Protein Science Roche Sanofi Pasteur Serum Indian Institute Pvt. Ltd. SmithKline Beecham Takeda Themis Bioscience
Organizations Mentioned in the Report Centers for Disease Control and Protection (CDC) Centre for Biologics Evaluation and Research (CBER) Developing Countries Vaccine Manufacturers Network (DCVMN) European Medicines Agency (EMA) Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Food and Drug Administration (FDA) Global Alliance for Vaccines Global Alliance for Vaccines and Immunization (GAVI) International Financing Facility for Immunisation National Health Service (NHS) Pan American Health Organization (PAHO) The Butantan Institute The Indian Department of Biotech The Ministry of Health, Labour and Welfare and the Health Service Bureau UNICEF World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Global Vaccines Sales Market Forecast 2019-2029
The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report
The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.
“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report
Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.
“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report
Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.
